“Our QUELIMMUNE net revenue in the first quarter was $495,000, a solid increase of 69% from the first quarter of last year,” said (Senior Vice President of Commercial & Business Operations Tim Varacek ...

SCD Therapy Clinical Recognition -- Featured in two American Society of Nephrology Kidney News articles highlighting its ...

House Bill 2002, which funds the Department of Elementary and Secondary Education, passed 83-68, just one vote above the ...

CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first ...

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10 percent of ...

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10% of people with ...

Sickle cell disease (SCD) is the most common inherited blood disorder in the United States. Approximately 10 percent of people with SCD in the US live ...

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the first quarter of 2026, narrower than the Zacks ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with ...

By bridging traditionally siloed systems — like clinical data integration and climate-resilient urban design — Massachusetts ...